US Patent

US11925709 — Tablet formulation for CGRP active compounds

Formulation · Assigned to Merck Sharp and Dohme LLC · Expires 2035-01-30 · 9y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a tablet formulation for releasing a compound, specifically a CGRP active compound, that rapidly disintegrates in the environment.

USPTO Abstract

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein “R a ” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Drugs covered by this patent

Patent Metadata

Patent number
US11925709
Jurisdiction
US
Classification
Formulation
Expires
2035-01-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.